|
WO2021005484A1
|
|
Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
|
|
WO2020261294A1
|
|
Novel apoptosis signal-regulating kinase 1 inhibitors
|
|
WO2021005436A1
|
|
Combination therapy of gpr119 agonists and dpp-4 inhibitors
|
|
US2020317661A1
|
|
GPR119 agonist compounds
|
|
WO2020240586A1
|
|
Novel compounds for inhibition of janus kinase 1
|
|
WO2020194115A1
|
|
Process for the preparation of elagolix sodium and intermediates thereof
|
|
WO2020178672A1
|
|
Ophthalmic composition of bimatoprost
|
|
WO2020115628A1
|
|
Solid forms of elafibranor and process of preparation thereof
|
|
WO2020039297A1
|
|
Novel compounds and their use in preparation of elafibranor and pharmaceutical acceptable salts thereof
|
|
US2021008152A1
|
|
Stable pharmaceutical composition of vasopressin
|
|
WO2019171260A1
|
|
Pharmaceutical composition of lifitegrast
|
|
WO2019130166A1
|
|
Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
|
|
EP3498698A1
|
|
Solid forms of valsartan disodium and process of preparation thereof
|
|
US2020330433A1
|
|
Extended release pharmaceutical composition of apremilast
|
|
US2020306242A1
|
|
Novel process for the preparation of lifitegrast
|
|
US2020222326A1
|
|
Fixed dose pharmaceutical composition of valsartan and sacubitril
|
|
US2017291894A1
|
|
GPR119 agonist compounds
|
|
US2017291910A1
|
|
Compounds as GPR119 agonists
|
|
US2017362197A1
|
|
Fluoroquinolone carboxylic acid compounds and use thereof for the preparation of besifloxacin hydrochloride
|
|
EP2984070A1
|
|
N-haloalkylindoline intermediates, their process and use in preparation of silodosin and its derivatives
|
